Harbour BioMed Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 183

Employees

  • Stock Symbol
  • 02142

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.99
  • (As of Thursday Closing)

Harbour BioMed General Information

Description

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.

Contact Information

Formerly Known As
HBM Holdings
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • The Harbourfront 18 Tak Fung Street
  • Unit 1607 A, Floor 16, Office Tower One
  • Kowloon, 348
  • Hong Kong
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • The Harbourfront 18 Tak Fung Street
  • Unit 1607 A, Floor 16, Office Tower One
  • Kowloon, 348
  • Hong Kong

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Harbour BioMed Stock Performance

As of 19-Jun-2025, Harbour BioMed’s stock price is $0.99. Its current market cap is $788M with 794M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.99 $1.05 $0.14 - $1.29 $788M 794M 11.7M

Harbour BioMed Financials Summary

As of 31-Dec-2024, Harbour BioMed has a trailing 12-month revenue of $38.1M.

In Thousands,
USD
TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 59,718 59,718 85,752 126,726
Revenue 38,100 38,100 89,502 40,659
EBITDA 3,346 3,346 25,561 (129,864)
Net Income 2,778 2,778 22,797 (137,222)
Total Assets 215,014 215,014 228,480 232,123
Total Debt 61,339 61,339 66,012 90,929
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Harbour BioMed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Harbour BioMed‘s full profile, request access.

Request a free trial

Harbour BioMed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiate
Drug Discovery
Kowloon, Hong Kong
183 As of 2024

Beijing, China
 

Shanghai, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Harbour BioMed Competitors (97)

One of Harbour BioMed’s 97 competitors is Brii Biosciences, a Formerly VC-backed company based in Beijing, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Brii Biosciences Formerly VC-backed Beijing, China
CARsgen Therapeutics Formerly VC-backed Shanghai, China
Zai Lab Formerly VC-backed Shanghai, China
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Clover Biopharmaceuticals Formerly VC-backed Shanghai, China
You’re viewing 5 of 97 competitors. Get the full list »

Harbour BioMed Patents

Harbour BioMed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023372213-A1 Bcma vh-only cars Pending 04-Nov-2022
EP-4526347-A1 Anti-cd200r1 antibodies Pending 19-May-2022
EP-4506366-A1 Antigen-binding protein targeting pd-l1 and cd40, preparation therefor, and use thereof Pending 02-Apr-2022
EP-4506364-A1 Antigen binding protein targeting cd40, and preparation therefor and use thereof Pending 02-Apr-2022
JP-2025511356-A Antigen-binding proteins targeting pd-l1 and cd40 and their production and application Pending 02-Apr-2022 C07K16/2878
To view Harbour BioMed’s complete patent history, request access »

Harbour BioMed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Harbour BioMed Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Harbour BioMed‘s full profile, request access.

Request a free trial

Harbour BioMed Investments & Acquisitions (3)

Harbour BioMed’s most recent deal was a Early Stage VC with Windward Bio for . The deal was made on 10-Jan-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Windward Bio 10-Jan-2025 Early Stage VC Drug Discovery
Harbour Antibodies 19-Dec-2016 Merger/Acquisition Drug Discovery
HBM Alpha Joint Venture Biotechnology
To view Harbour BioMed’s complete investments and acquisitions history, request access »

Harbour BioMed Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Harbour Antibodies 2006

Harbour BioMed FAQs

  • When was Harbour BioMed founded?

    Harbour BioMed was founded in 2016.

  • Where is Harbour BioMed headquartered?

    Harbour BioMed is headquartered in Kowloon, Hong Kong.

  • What is the size of Harbour BioMed?

    Harbour BioMed has 183 total employees.

  • What industry is Harbour BioMed in?

    Harbour BioMed’s primary industry is Drug Discovery.

  • Is Harbour BioMed a private or public company?

    Harbour BioMed is a Public company.

  • What is Harbour BioMed’s stock symbol?

    The ticker symbol for Harbour BioMed is 02142.

  • What is the current stock price of Harbour BioMed?

    As of 19-Jun-2025 the stock price of Harbour BioMed is $0.99.

  • What is the current market cap of Harbour BioMed?

    The current market capitalization of Harbour BioMed is $788M.

  • What is Harbour BioMed’s current revenue?

    The trailing twelve month revenue for Harbour BioMed is $38.1M.

  • Who are Harbour BioMed’s competitors?

    Brii Biosciences, CARsgen Therapeutics, Zai Lab, Inovio Pharmaceuticals, and Clover Biopharmaceuticals are some of the 97 competitors of Harbour BioMed.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »